[
  {
    "ts": "2026-01-11T19:00:00+00:00",
    "headline": "Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome",
    "summary": "BEDFORD, Mass., January 11, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR",
    "url": "https://finance.yahoo.com/news/stoke-therapeutics-announces-updates-timelines-190000453.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "5721834f-4434-35b2-853a-d63b894fdce9",
      "content": {
        "id": "5721834f-4434-35b2-853a-d63b894fdce9",
        "contentType": "STORY",
        "title": "Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome",
        "description": "",
        "summary": "BEDFORD, Mass., January 11, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR",
        "pubDate": "2026-01-11T19:00:00Z",
        "displayTime": "2026-01-11T19:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/566b2856d1ecf5e4f6f25e875e6af62c",
          "originalWidth": 480,
          "originalHeight": 223,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ob_xn66geaf9kEaPSlKY9w--~B/aD0yMjM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/566b2856d1ecf5e4f6f25e875e6af62c.cf.webp",
              "width": 480,
              "height": 223,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/crPlljYmvl2s39VMSa8VwA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/566b2856d1ecf5e4f6f25e875e6af62c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-announces-updates-timelines-190000453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-announces-updates-timelines-190000453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STOK"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]